Gene expression profiling of triple-negative breast tumors with different expression of secreted protein acidic and cysteine rich (SPARC)

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author ALCANTARA FILHO, Paulo R. de FMUSP-HC
MANGONE, Flavia R. FMUSP-HC
PAVANELLI, Ana C. FMUSP-HC
GARCIA, Simone A. de Bessa FMUSP-HC
NONOGAKI, Suely
OSORIO, Cynthia A. B. de Toledo
ANDRADE, Victor P. de
NAGAI, Maria A. FMUSP-HC
dc.date.issued 2018
dc.identifier.citation BREAST CANCER MANAGEMENT, v.7, n.2, article ID UNSP BMT09, 18p, 2018
dc.identifier.issn 1758-1923
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/29897
dc.description.abstract Aim: To determine the expression signature of triple-negative breast cancer (TNBC) with differences of secreted protein acidic and rich in cysteine expression and clinical behavior. Patients, materials & methods: cDNA microarray analysis was performed to determine the expression profiling of TNBC, characterized regarding secreted protein acidic and rich in cysteine expression status. Immunohistochemistry analysis on tissue microarrays containing an independent cohort of TNBC was performed for validation. Results: Negative staining of SOHLH2 and positive staining of DNAJC12 and LIM1 was correlated with a poor outcome of the patients. Conclusion: Our findings provide new information on transcriptome changes associated with the clinical behavior of TNBC that may serve as a potential tool for the identification and characterization of new candidate biomarkers.
dc.description.sponsorship · Fundaco de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/07035-4]
· Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [303134/2013-5]
dc.language.iso eng
dc.publisher FUTURE MEDICINE LTD
dc.relation.ispartof Breast Cancer Management
dc.rights openAccess
dc.subject expression profiling; immunohistochemistry; protein expression; SPARC; tissue microarray; triple-negative breast cancer
dc.subject.other cancer patients; ovarian-cancer; neck-cancer; overexpression; prevalence; recurrence; estrogen; therapy; subtype; sohlh2
dc.title Gene expression profiling of triple-negative breast tumors with different expression of secreted protein acidic and cysteine rich (SPARC)
dc.type article
dc.rights.holder Copyright FUTURE MEDICINE LTD
dc.description.group LIM/24
dc.identifier.doi 10.2217/bmt-2017-0019
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author ALCANTARA FILHO, Paulo R. de:FM:
hcfmusp.author MANGONE, Flavia R.:HC:ICESP
hcfmusp.author PAVANELLI, Ana C.:HC:ICESP
hcfmusp.author GARCIA, Simone A. de Bessa:FM:MDR
hcfmusp.author NAGAI, Maria A.:FM:MDR
hcfmusp.author.external · NONOGAKI, Suely:AC Camargo Canc Ctr, Dept Pathol, BR-01509020 Sao Paulo, Brazil
· OSORIO, Cynthia A. B. de Toledo:AC Camargo Canc Ctr, Dept Pathol, BR-01509020 Sao Paulo, Brazil
· ANDRADE, Victor P. de:AC Camargo Canc Ctr, Dept Pathol, BR-01509020 Sao Paulo, Brazil
hcfmusp.origem.id WOS:000448922300001
hcfmusp.publisher.city LONDON
hcfmusp.publisher.country ENGLAND
hcfmusp.relation.reference · Ahn SG, 2016, J BREAST CANCER, V19, P223, DOI 10.4048/jbc.2016.19.3.223
· Ali AM, 2017, ANTI-CANCER AGENT ME, V17, P491, DOI 10.2174/1871520616666160725112335
· Arnold SA, 2009, J CELL COMMUN SIGNAL, V3, P255, DOI 10.1007/s12079-009-0072-4
· Arvold ND, 2011, J CLIN ONCOL, V29, P3885, DOI 10.1200/JCO.2011.36.1105
· Bagheri-Yarmand R, 2006, INT J CANCER, V118, P2703, DOI 10.1002/ijc.21650
· Ballow DJ, 2006, GENE EXPR PATTERNS, V6, P1014, DOI 10.1016/j.modgep.2006.04.007
· Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187
· Bradshaw AD, 2012, INT J BIOCHEM CELL B, V44, P480, DOI 10.1016/j.biocel.2011.12.021
· Brekken Rolf A., 2001, Matrix Biology, V19, P816
· Brown TJ, 1999, GYNECOL ONCOL, V75, P25, DOI 10.1006/gyno.1999.5552
· Byrski T, 2009, BREAST CANCER RES TR, V115, P359, DOI 10.1007/s10549-008-0128-9
· Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019
· Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
· Chin D, 2005, INT J CANCER, V113, P789, DOI 10.1002/ijc.20608
· Choi J, 2014, CELL STRESS CHAPERON, V19, P439, DOI 10.1007/s12192-013-0471-6
· CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
· Colleoni M, 2010, J CLIN ONCOL, V28, P2966, DOI 10.1200/JCO.2009.25.9549
· Cossetti RJD, 2015, J CLIN ONCOL, V33, P65, DOI 10.1200/JCO.2014.57.2461
· Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
· Garcia SAD, 2017, INT J MOL MED, V39, P809, DOI 10.3892/ijmm.2017.2900
· De Bessa SA, 2006, INT J MOL MED, V17, P363
· Desai N, 2009, TRANSL ONCOL, V2, P59, DOI 10.1593/tlo.09109
· Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
· Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
· Engebraaten O, 2013, AM J PATHOL, V183, P1064, DOI 10.1016/j.ajpath.2013.05.033
· Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
· Fostira F, 2012, BREAST CANCER RES TR, V134, P353, DOI 10.1007/s10549-012-2021-9
· Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
· Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091
· Fujita T, 2002, J ORAL PATHOL MED, V31, P345, DOI 10.1034/j.1600-0714.2002.00188.x
· Golembieski WA, 2002, J NEURO-ONCOL, V60, P213, DOI 10.1023/A:1021167211131
· Greenup R, 2013, ANN SURG ONCOL, V20, P3254, DOI 10.1245/s10434-013-3205-1
· He HL, 2015, EXP MOL PATHOL, V98, P338, DOI 10.1016/j.yexmp.2015.03.029
· Herschkowitz JI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2142
· Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
· Ji SF, 2016, ONCOTARGET, V7, P49411, DOI 10.18632/oncotarget.10355
· Kurebayashi J, 2007, BREAST, V16, pS72, DOI 10.1016/j.breast.2007.07.017
· LANE TF, 1992, J BIOL CHEM, V267, P16736
· Lee J, 2000, BBA-GENE STRUCT EXPR, V1491, P355, DOI 10.1016/S0167-4781(00)00047-6
· Lukk M, 2010, NAT BIOTECHNOL, V28, P322, DOI 10.1038/nbt0410-322
· Matthews JM, 2013, NAT REV CANCER, V13, P111, DOI 10.1038/nrc3418
· Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x
· Montanez-Wiscovich ME, 2009, ONCOGENE, V28, P3608, DOI 10.1038/onc.2009.221
· Nagai MA, 2004, INT J CANCER, V111, P892, DOI 10.1002/ijc.20329
· Nagai MA, 2011, BREAST CANCER RES TR, V126, P1, DOI 10.1007/s10549-010-0867-2
· Noh JM, 2011, J BREAST CANCER, V14, P46, DOI 10.4048/jbc.2011.14.1.46
· Pareja F, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2016.36
· Partridge AH, 2016, J CLIN ONCOL, V34, P3308, DOI 10.1200/JCO.2015.65.8013
· PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114
· Qiu XB, 2006, CELL MOL LIFE SCI, V63, P2560, DOI 10.1007/s00018-006-6192-6
· Rakha EA, 2009, PATHOLOGY, V41, P40, DOI 10.1080/00313020802563510
· Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
· Singh RR, 2005, CANCER RES, V65, P10594, DOI 10.1158/0008-5472.CAN-05-2268
· Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102
· Sun Hong, 2007, Transl Oncogenomics, V2, P107
· Suzuki H, 2012, DEV BIOL, V361, P301, DOI 10.1016/j.ydbio.2011.10.027
· Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337
· Tai IT, 2005, J CLIN INVEST, V115, P1492, DOI 10.1172/JCI23002
· Toyoda S, 2009, DEV BIOL, V325, P238, DOI 10.1016/j.ydbio.2008.10.019
· Wang CS, 2004, BRIT J CANCER, V91, P1924, DOI 10.1038/sj.bjc.6602213
· Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
· Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100
· Zhang HY, 2014, CARCINOGENESIS, V35, P1863, DOI 10.1093/carcin/bgu113
dc.description.index PubMed
dc.identifier.eissn 1758-1931
hcfmusp.citation.wos 0
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics